Page 76 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy

gastric/gastroesophageal junction adenocarcinoma. J Immunother Cancer,
2015. 3.
36. Lutzky, J., et al., A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in
patients with advanced solid tumors. J Clin Oncol, 2014. 32(15).
37. Hodi, F.S., et al., MPDL3280A (anti-PDL1): Clinical activity, safety and biomarkers of an engineered PD-L1 antibody in patients with locally
advanced or metastatic tumors. Eur J Cancer, 2013. 49: p. S184.
38. Kohrt, H., et al., Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1. J Immunother Cancer,
2013. 1.
39. Herbst, R.S., et al., Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature, 2014. 515(7528): p. 563-
567.
40. Roy, S.H., et al., A phase 1 study of ramucirumab (R) plus pembrolizumab
(P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. Journal of Clinical Oncology, 2016. 34(15_suppl): p. 3056-3056.
41. Gold, P., et al., P3.02c-011 A Phase 1b Open-Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan-High Solid Tumors. Journal of Thoracic Oncology. 12(1): p. S1278.
42. Zev, A.W., et al., Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. Journal of Clinical Oncology, 2016. 34(4_suppl): p. TPS465-TPS465.
43. Karen, K., et al., Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial. Journal of Clinical Oncology, 2016. 34(15_suppl): p. 3055-3055.
44. Yasuhide, Y., et al., A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer. Journal of Clinical Oncology, 2015. 33(15_suppl): p. 4047-4047.
Chapter 3
Chapter 3
70
74